ABSTRACT Introduction: The aim of this study is to compare molecule removal and albumin leakage in postdilution online hemodiafiltration with different high-flux dialyzers. Methods: We studied seven high-flux dialyzers (Polyflux 210H
INTRODUCTION
The use of high hydraulic permeability membranes (highflux) with a high ß2 microglobulin sieving coefficient has increased to enhance the depuration of middle-to-largesized molecules. The clinical benefit of high-flux dialysis has not been clearly demonstrated, as the HEMO study failed to demonstrate a decrease in all-cause mortality using high-flux dialysis compared with that of low-flux dialysis. 1 However, the Membrane Permeability Outcome (MPO) study and a posthoc analysis in diabetic patients showed that high-flux hemodialysis improved long-term survival in patients with serum albumin ≤4 g/dL.
2 Online hemodiafiltration (OL-HDF) with a high volume of replacement combines diffusive with convective treatment, allows a greater clearance of solutes of medium and high molecular weight and improves intradialysis hemodynamic tolerance. Moreover, high-flux membranes used in postdilution OL-HDF with a high convective volume reduce mortality from any cause with respect to hemodialysis (HD) in prevalent patients on HD.
Membrane performance, which is determined by the efficacy in solute clearance and biocompatibility, is a major concern when choosing a dialyzer. Technological advances in membrane design, chemical composition and sterilization methods have led to enhanced performance and versatility to the extent that dialyzer choice may reduce morbidity and prolong survival. Thus, along with performance parameters, it is the clinician's challenge to find the optimal dialyzer based on different membrane characteristics. However, there is a wide variety of unresolved issues, such as the difference between high-flux dialyzers in terms of the elimination of middle-to-large-sized molecules, whether the use of the membranes with the greatest efficacy could result in better outcomes, or whether the dialyzer class could affect albumin loss into the dialysis fluid during a dialysis session.
The aim of this prospective study is to compare the clearance of middle-to-large-sized molecules and albumin leakage in postdilution OL-HDF using different high-flux membrane dialyzers.
MATERIALS AND METHODS

Patients
Six adult stage 5D kidney disease patients (4 males, 2 females) who had been on thrice weekly maintenance OL-HDF for at least 6 months were enrolled in the study.
The following inclusion criteria were applied: age older than 18 years; dialysis sessions of 4 hours, 3 days per week for at least 6 months; blood flow >400 mL/minute and convective volume > 30 L in the regular sessions; and stable clinical conditions defined as the absence of hospital admission in the 4 weeks prior to the start of the study. Patients who failed to meet the above mentioned inclusion criteria were excluded.
Demographic and clinical data collected were age, gender, ESRD etiology, dialysis vintage, and vascular access and presence of residual renal function (RRF) interpreted as daily diuresis >500 mL. The urea distribution volume was obtained using spectroscopy multifrequency bioimpedance (BCM ® , FMC). The dialysis parameters collected in each session were as follows: programmed time, real duration, dialyzer, Qb, Qd, caliber of the needles, Kt automatically measured by ionic dialysance, arterial pressure, venous pressure, transmembrane pressure, initial and final hematocrit, ultrafiltration (UF), volume of blood processed, and substitution volume. Written informed consent was obtained from all patients. All procedures were in accordance with the Declaration of Helsinki and its revisions.
Study design
The study was conducted using a prospective, cross-over, open-label design. Every treatment was performed using high-flux membranes. The following dialyzers were included: Details of the dialyzers are presented in Table 1 . All patients received one middle-week session using each dialyzer included in the study. Due to logistical reasons, we evaluated the same dialyzer each week in all patients. Dialyzers were used consecutively in the order previously described. Between the reallocation of each filter, at least one wash-out week was always included. The OL-HDF parameters and filter during the wash-out week were prescribed according to the patient's previous treatment.
A new dialyzer was used for each study treatment, and there was no dialyzer reuse. All filters were prerinsed with 1000 mL 0.9% NaCl fluid before every session.
Treatment characteristics
Monitoring was performed using AK200 ULTRA S (Baxter Healthcare Ltd.) and 5008 Cordiax (Fresenius Medical Care, Bad Homburg, Germany) monitors. The monitors were programmed using control-volume to obtain 24 L of substitution with each filter in all patients. The dialysis features prescribed included blood flow (Q b ) at 400 mL/minute, which was maintained during the whole session, and dialysate flow (Q d ) at 700 mL/minute. The total convective volume was assumed as 24 L plus ultrafiltration volume (UF).
Ultrapure dialysis fluid was used for all treatments (including the wash-out period). Anticoagulation was achieved with unfractionated heparin administered as an initial bolus dose followed by a second dose in the second hour of the dialysis. The doses of heparin were unchanged during this study. Samples were collected during the mid-week session of each respective period. The serum concentration of different molecular weight molecules: urea (60 Da), creatinine (113 Da), phosphorus (30 Da), ß2 microglobulin (11.8 kDa), myoglobin (17.2 kDa), prolactin (23 kDa), and albumin leakage were analyzed as explained below. Among these parameters, urea, creatinine and phosphorous were regarded as small-molecule solutes; β2-microglobulin, myoglobin and prolactin were considered middle-molecule solutes.
Sample collection and laboratory analysis
The change in solute concentration over the entire treatment was determined from predialysis and postdialysis blood samples. Predialysis blood samples were drawn from the access needle immediately following needle insertion. Postdialysis blood samples were drawn from the arterial blood line exactly 30 seconds after setting the blood pump at 50 mL/minutes to mitigate any access recirculation. Concentrations of urea, creatinine, phosphorus, and albumin were determined using standard clinical laboratory methods. ß2 microglobulin was measured using a nephelometric inmmunoassay (Immulite 2000, Siemens, Erlangen, Germany), and myoglobin and prolactin were measured via electrochemiluminescence using a specific Cobas analyzer (Roche Diagnostics, Basel, Switzerland). The final concentration of ß2 microglobulin, myoglobin, prolactin and albumin were corrected for the degree of hemoconcentration and the volume of distribution (approximately the extracellular volume) according to Bergström and Wehle 4 as follows:
The reduction ratio (RR) of every solute studied was calculated using predialysis (C pre ) and postdialysis (C post ) concentrations according to the following formula:
where C is the concentration (either before or after treatment: C pre and C post , respectively). Likewise, a proportional part of the dialysis fluid was collected at the beginning (once blood flow and UF were stabilized), and at 15, 30, 60, and 120 minutes to quantify the loss of albumin. The albumin concentration was measured using an autoanalyzer (Dimension RXL, DADE, Siemens, Erlangen, Germany) in the Biochemistry Department. The dialysate flux values were recorded at these time points. Thus, assuming that the albumin losses decrease over time during the session, we were able to estimate the amount of total leakage (EAL) in each period (0-15 minutes, 15-30 minutes, 30-60 minutes, 60-120 minutes, and 120-240 minutes) using the following formula K UF = ultrafiltration coefficient; KoA = mass transfer urea coefficient; Sc = sieving coefficient; PA = polyamide; PES = polyethersulfone; PVP = polyvinylpyrrolidone; PS = polysulfone; AN69 ST = acrylonitrile and sodium methallyl sulfonate copolymer; NG = not given.
EAL: estimated albumin loss (mg/session); C: albumin concentration in the dialysate at the beginning (C 0 ), at 15 minutes (C15), at 30 minutes (C30), at 60 minutes (C60) and at 120 minutes (C120); UF: ultrafiltration (L); Sust: substitution volume (L); Qd: dialysate flow (mL/minute). This formula assumes that the albumin concentration in the dialysate during the periods from 0 to 15, from 15 to 30, from 30 to 60 and from 60 to 120 minutes is the average of the concentrations at the beginning and at the end of each period and that the concentration at the second hour is maintained until the end of the treatment.
Statistical methods
Statistical comparisons were made among the seven membrane types. Data were checked for normality using the Kolmogorov-Smirnov test. The descriptive results are expressed as the means AE standard deviation for normally distributed quantitative variables and the median values (interquartile ranges) for abnormally distributed quantitative variables. The qualitative variables are reported as percentages. One-factor ANOVA followed by Bonferroni's posthoc comparisons tests were performed for the parametric data. The Kruskal-Wallis test was performed for the nonparametric data. A value of P < 0.05 was considered statistically significant with a 95% confidence interval. All analyses were performed using the SPSS software, version 20.0 for Mac (SPSS, Inc., Chicago, IL, USA).
RESULTS
Six patients were included (4 males, 2 females), with a mean age of 68.33 AE 17.08 years. The cause of chronic kidney disease was glomerulonephritis in 3 patients, unknown in 2 patients, and diabetic nephropathy in 1 patient. The dialysis vintage was 49.83 AE 24.91 months. All patients had a permanent native or prosthetic arteriovenous fistula, capable of delivering an effective blood flow rate (Q B eff , blood flow corrected for the effect of the negative arterial pressure) of at least 450 mL/minute, without significant access recirculation (<10%). None of the patients had RRF (diuresis >500 mL per day). The median hematocrit was 35.2 AE 6.5%, and the mean serum protein level was 6.6 AE 1.5 g/dL. All patients completed the experimental sessions of all treatments with no technical problems. In particular, there were no occurrences of blood circuit clotting, and the regularity of the sessions was not compromised by hypotensive episodes or other clinical problems. There were no differences in the following dialysis parameters: Q b , Q d , real duration of sessions, size of the needles, recirculation of the vascular access, arterial pressure, venous pressure, or transmembrane pressure. The serum predialysis levels of different molecules with each dialyzer are represented in Table 2 .
Small molecules
The RR of the small molecules (creatinine, urea, and phosphorus) referred to the dialyzer type according to the UF coefficient (K UF ) and is represented in Table 3 . Comparing the seven dialyzers, the reduction ratio of the small compounds was not significantly different across the dialyzers.
Middle compounds
The reduction ratios of the middle molecules across the seven different dialyzers included in our study and the mean convective volume (UF plus substitution volume) with each type of filter are shown in Table 3 . We found no differences in total convective volume. Comparing the seven dialyzers, global differences were observed in ß2 microglobulin RR (P = 0.003). The ß2 microglobulin RR ranged from 72.2 AE 2.8% (achieved with Evodial 2.2) to 85.9 AE 2.9% (with Xevonta-Hi20). The RR using the Evodial 2.2 dialyzer achieved significantly less ß2 microglobulin than that achieved using the FXCordiax 1000 (P = 0.023), TS2.1SL (P = 0.043), XevontaHi20 (P = 0.012), and VitaPES210-HF (P = 0.023) dialyzers. No significant differences were found in the B2-microglobulin RR among the FXCordiax1000, TS2.1SL, VitaPES210HF, and XevontaHi20 dialyzers. The RR of myoglobin ranged from 60.5 AE 8.1% (with Polyflux210H) to 72.4 AE 4.7% (with VitaPES210-HF). We found no significant differences between dialyzers for the RR of myoglobin. We found global differences in the RR of prolactin RR (P = 0.013). The RR of prolactin ranged from 55.6 AE 17.41% (with Polyflux210H) to 71.8 AE 9.6% (with FXCordiax1000). Table 4 shows albumin losses associated with the different dialyzers, and it is represented in time in Figure 1 . The mean loss of albumin in the dialysate per session varied between 114 AE 67 mg per session (using the Evodial 2.2 dialyzer) to 2621 AE 1363 mg per session (using the XevontaHi20 dialyzer). We found global differences between dialyzers for total albumin loss (P = 0.05); however, we could not demonstrate differences in albumin loss in the first 2 hours (P = 0.06). The Evodial 2.2 dialyzer achieved less total albumin loss compared to that using the XevontaHi20 dialyzer (114 AE 67 mg/session vs. 2621 AE 1363 mg/session, respectively, P = 0.03).
Albumin
DISCUSSION
This study evaluates the impact of membrane manufacturing on the removal of uremic solutes during OL-HDF. To date, no other study has evaluated the membrane performance of 7 different types of high-flux dialyzers in OL-HDF. The current standard for adequate dialysis is based on the removal of urea. 6 However, urea removal by HD depends mostly on diffusion. Therefore, the choice of dialyzer has a much smaller impact considering the dialyzers currently in clinical use. According to that we found no significant differences in the RR of small molecules among the different dialyzers used in our study. An essential requirement in modern HD is the removal of medium-and large-sized uremic toxins. In this setting, the choice of dialyzer becomes a more important determinant of the removal of middle-sized molecules.
Because it is easy to measure, ß2 microglobulin is now considered a surrogate marker for the removal of middlesized molecules. The membrane sieving coefficient for ß2 microglobulin has gained acceptance by both dialyzer manufacturers and the medical community for the assessment of membrane flux.
7,8
In our study, all seven dialyzers had a high UF coefficient (K UF ; ranged from 55 to 111 mL/h/mmHg) and high solute permeability measured by mass transfer urea (K O A; ranged from 1421 to 1976 mL/h/mmHg). ß2 microglobulin sieving coefficient was high for all of the dialyzers, with a value from 0.7 to 0.9. These filter characteristics were considered to be equal. However, we found significant differences in ß2 microglobulin removal a follows: The Evodial 2.2 dialyzer achieved a lower reduction ratio than that of the other dialyzers. This draws attention as the ß2 microglobulin RR associated with the Evodial 2.2 dialyzer was even less than that of other dialyzers that had a lower K UF (55 mL/h/mmHg): 72.2 AE 2.3% vs. 84.3 AE 2.3%, P = 0.043, respectively. The ß2 microglobulin sieving coefficient was not determined for the Evodial 2.2 dialyzer, thus so we cannot compare both dialyzers in terms of the ß2 microglobulin sieving coefficient. Similarly, a better ß2 microglobulin RR was associated with the XevontaHi20 (K UF 111 mL/h/mmHg and ß2 microglobulin sieving coefficient > 0.8). We could not demonstrate differences in myoglobin removal among the dialyzers. Nevertheless, we found a significant difference in the removal of prolactin, which is a higher molecular weight protein than myoglobin (17.2 vs. 23 kDa). This is likely to be due to the different membrane morphology, less adsorptive capacity and properties of the protein, including not only the molecular size but also its charge, hydrophobicity and any post-translational modifications associated with uremia that may affect the rigidity of the protein. Collectively, these properties may influence the interaction of the protein with the membrane material and affect the ability of the protein to pass through the membrane by convection or adsorption. The removal of middle-sized molecules via the Evodial 2.2 dialyzer did not exceed those achieved with any other dialyzer. One possible explanation is that the structure of the Evodial 2.2 dialyzer with heparin grafted to the membrane, does not allow high molecular weight proteins to pass through it. As previously reported, 9 albumin leakage depends on the dialyzer used. Interestingly, we found that albumin leakage was higher than specified by its sieving coefficient indicated in technical data sheet. This is motivated mainly because of the difference in prescription parameters when testing the filters in the laboratory. When considering clinical practice, a higher intradialyzer pressure is achieved, leading to increased albumin leakage.
In our study, we used the same blood flow, dialysate flow, and substitution volume in all patients with the different dialyzers to assess albumin leakage in conditions similar to regular clinical practice. We could not demonstrate differences in albumin loss in the first 2 hours of treatment, probably due to the small sample size. However, we found that the total estimated albumin loss during the session was significantly different. One possible explanation could be the greater pressure generated in those dialyzers with a small inner diameter of the hollow fiber, leading to increased albumin loss. However, Maduell et al. did not find any differences in albumin loss when the inner diameter of the capillary fibers of the dialyzer was changed from 185 to 210 μm using the helixone plus membrane. 10 In our study, less albumin leakage was achieved using the Evodial 2.2 dialyzer. Our group hypothesized that the decreased albumin leakage was related to the membrane composition. The Evodial 2.2 dialyzer consists of AN96 ST, an acrylonitrile and sodium methallyl sulfonate copolymer-Polyethyleneimineheparin-grafted membrane. The heparin charges and membrane composition affect the membrane-protein interaction, leading to differences in the ability of albumin to pass through the dialyzer.
Macías et al. demonstrated that the estimated albumin loss into the dialysis fluid was not related to laboratory or bioimpedance nutritional parameters, 5 although this association has been proposed by other groups. 11 Thus, the pathophysiologic impact of transmembrane albumin losses during dialysis remains currently unclear. It would be interesting to assess changes in plasma albumin and other nutritional parameters with long-term use of each dialyzer.
Comparisons with previous studies are rather difficult because of different treatment parameters. Compared to the RR values in the study of Maduell et al., 12 we found similar RRs for ß2 microglobulin and myoglobin. However, in comparison to the study of Meert et al., 13 we found a similar RR for ß2 microglobulin, but a higher myoglobin RR in postdilutional HDF-OL. Although, they did not study prolactin removal, we compared the RR of retinol-binding protein (molecular weight: 21.2KDa) to the prolactine (23KDa) RR in our study. The differences observed are probably due to the different OL-HDF prescription, with a higher convective treatment in our patients.
During the last few years, new dialyzers have been developed that have a greater surface area, better geometric arrangement of capillary fibers, variation in wall thickness, and a larger pore size to achieve greater removal of both small-, medium-, and large-sized molecules. The ideal hemodialyzer should achieve the following characteristics: a high clearance of small molecules; high sieving coefficient for ß2 microglobulin and myoglobin; low sieving coefficient for albumin; low transmembrane pressures that do not limit the infusion flow; great power to trap endotoxins and a good price. 14 This study was developed as an acute study focusing on the reduction of serum concentration molecules during one OL-HDF session. Although, it is difficult to predict the clinical relevance, we could demonstrate that not all high-flux dialyzers should be considered equal, and we think our study is useful for a better comprehension of dialyzers in convective therapies.
Our study has some limitations. First, our study population was small, and the power to detect differences was also limited. The reduction ratio is the result of several processes, and extracorporeal clearance is only one of them. Therefore, results should be interpreted with care as the calculated RR may over-estimate the true removal of solutes with multicompartmental kinetics. Moreover, in our study, we did not analyze protein-bound compounds, thus more studies are needed in this regard. However, as stated by others authors, 15 our results stress that high-flux membranes are not equal. Taking into account the limitations of our study, it has been demonstrated that high-flux membrane performance is different among the various types of dialyzers. Thus, we can assess that the choice of dialyzer is a complex decision and one of the most important tools that clinicians should use to improve efficacy in solute clearance while minimizing albumin leakage. Whether the new generation of dialyzers has a positive impact on clinical outcomes can only be demonstrated by long-term clinical studies using a similar design.
CONCLUSIONS
Our study confirms that not all large pore membranes should be considered the same, even if the pore size or the polymers from which they are made are identical. A higher UF coefficient does not necessarily lead to improvement in molecule removal or higher albumin leakage. Individual patient needs should be factored into the dialyzer selection. Along with performance parameters, it is the clinician's challenge to find the optimal dialyzer to remove specific solutes and minimize albumin losses.
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